Last reviewed · How we verify
Carbetocin Short-infusion
Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote hemostasis.
Carbetocin is a synthetic oxytocin analogue that binds to oxytocin receptors to stimulate uterine contractions and promote hemostasis. Used for Prevention and treatment of postpartum hemorrhage during cesarean delivery, Prevention and treatment of postpartum hemorrhage during vaginal delivery.
At a glance
| Generic name | Carbetocin Short-infusion |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Oxytocin receptor agonist |
| Target | Oxytocin receptor |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Carbetocin mimics the natural hormone oxytocin by activating oxytocin receptors on uterine smooth muscle, triggering sustained contractions that compress bleeding vessels and reduce postpartum hemorrhage. It has a longer duration of action and more stable pharmacokinetics compared to oxytocin, making it suitable for short infusion administration during and after cesarean delivery or vaginal delivery.
Approved indications
- Prevention and treatment of postpartum hemorrhage during cesarean delivery
- Prevention and treatment of postpartum hemorrhage during vaginal delivery
Common side effects
- Hypertension
- Tachycardia
- Headache
- Nausea
- Flushing
Key clinical trials
- Carbetocin Versus Oral Tranexamic Acid Plus, Buccal Misoprostol on Blood Loss After Vaginal Delivery (NA)
- Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbetocin Short-infusion CI brief — competitive landscape report
- Carbetocin Short-infusion updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI